Navigation Links
Keryx Biopharmaceuticals Receives Nasdaq Notification
Date:4/25/2008

our actual results to differ materially are the following: There can be no assurance that the Company will apply for inclusion on the Nasdaq Capital Market, or if so, that the Company's application for inclusion on the Nasdaq Capital Market will be approved,, or that if approved and the listing is transferred, that the Company will continue to meet the Nasdaq Capital Market listing requirements, and/or if the Company's application is denied, that the Company will satisfy Nasdaq's conditions for continued listing on the Nasdaq Global Market, that any potential appeal or hearing for a stay of delisting from the Nasdaq Global Market will be successful, or that the Company's common stock will remain listed on the Nasdaq Global Market; that the Company will complete cost- effective clinical trials or meet as anticipated the development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401, to help generate greater interest in the market for its common stock; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965

E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
2. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
3. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
4. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
6. Keryx Biopharmaceuticals Announces Additions to Management Team
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
10. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
11. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... 2014 More than 5 million Americans ... in 3 seniors will die with Alzheimer’s or another ... figures have shocked many Americans into looking for ways ... these tragic age-related cognitive disorders. Jonathan Weisman, president of ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... April 12, 2011 Drs. Rodney Landreneau and ... non small cell lung cancer study at the 2011 Society ... Landreneau is Director of the Lung Center at UPMC Shady ... at UPMC Passavant Medical Center and Director of the Division ...
... 12, 2011 Biotech Medical, Inc. is set to ... SpectraSan™ "Hungry Enzymes". The products will be available for ... a Pet Stain & Odor Eraser, Spa & Whirlpool ... All-Purpose Cleaner & Degreaser, Glass & Stainless Steel Cleaner ...
... Dr. Fresh®, Inc., maker of the popular FireFly® children,s ... to raise awareness and funds for Smile Train, the ... company will donate $1 for every new "Like" on ... Smile Train.  The organization provides life-changing surgery for poor ...
Cached Biology Technology:Precision Therapeutics' ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer 2Biotech Medical, Inc. Introduces a Full Line of Enzyme Cleaners 2FireFly® Toothbrush Facebook Campaign Raises Funds for Smile Train 2
(Date:4/17/2014)... have hit on a novel method to help ... and most effective treatment possible., Kidney stones represent ... developing world. If left untreated, apart from being ... and other complications. In many patients treated successfully, ... more effective pathological approach to diagnosis and treatment ...
(Date:4/17/2014)... meeting painted a stark warning on the possible effects ... greenhouse effect 32 times that of carbon dioxide. Now ... substances act as fully regenerable electron acceptors which helps ... wetlands instead of being released to the atmosphere. However, ... it may enter into a vicious cycle to release ...
(Date:4/17/2014)... University researchers have detected new early-warning signs of the ... could have far-reaching implications for the diagnosis and treatment ... 25 million Americans. , "We had not expected to ... early stages," said Ann Elsner, professor and associate dean ... of the study. "We set out to study the ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... Gary Hoyle, PhD, professor, University of Louisville School of ... research to develop an effective medical treatment to counteract ... of terrorism. The National Institute of Environmental Health Sciences ... have awarded Hoyle $2.6 million over five-years to further ...
... in the southeastern United States, and for scientists trying to ... ) is not cooperating. So far botanists have ... plant to boiling water, dry heat up to 284 degrees ... coax them into germination. Nothing has worked. "Complete ...
... and conservation successes in the face of rapid environmental ... plants adapt to local climate. To improve scientists, ... 7, 2011 issue of Science helps define ... The National Science Foundation partly funded the study, ...
Cached Biology News:UofL researcher awarded $2.6 million NIH grant renewal 2Super-tough seed coat keeps Michaux's sumac on critically endangered list 2